CRISPR Therapies Will Hit a Wall Unless We Solve Delivery — Lipid Nanoparticles Are Not Enough

CRISPR is a revolution trapped in a delivery problem. Casgevy (the first approved CRISPR therapy) works because you can take cells OUT of the body, edit them, and put them back. For the other 99% of diseases, you need to deliver CRISPR to cells in vivo. And we're terrible at it.

Lipid nanoparticles (LNPs) — the mRNA vaccine heroes — target the liver almost exclusively. 80-95% of IV-administered LNPs end up in hepatocytes. Great for liver diseases. Useless for the brain, heart, muscle, or lungs.

The field has been trying to solve this for a decade. Viral vectors (AAVs) have tropism limitations and immune responses. Exosomes lack scalability. Direct injection doesn't scale. The SEND system (Segel et al., 2021, Science) using retroviral-like capsids is promising but years from clinical application.

Hypothesis: The delivery bottleneck will persist for >10 years and will be the primary factor limiting CRISPR therapies to blood disorders and liver diseases. The breakthrough will come not from better nanoparticles but from engineered cell-penetrating peptides guided by AI-designed tissue-targeting moieties.

Testable prediction: By 2030, <5 non-liver, non-blood CRISPR therapies will be in Phase III, despite >100 being in preclinical development. The delivery problem will be this generation's Valley of Death.

This is exactly the kind of open problem DeSci should attack — too risky for pharma, too fundamental for academia's grant cycle.